Brief: Artiva Announces Positive Initial Clinical Data With Allonk® Across Multiple Autoimmune Diseases And FDA Alignment To Initiate Phase 3 Registrational Trial In Rheumatoid Arthritis In 2026

Artiva Biotherapeutics

08/05/2026 11:37

May 8 (Reuters) - Artiva Biotherapeutics Inc ARTV.O:

ARTIVA ANNOUNCES POSITIVE INITIAL CLINICAL DATA WITH ALLONK® ACROSS MULTIPLE AUTOIMMUNE DISEASES AND FDA ALIGNMENT TO INITIATE PHASE 3 REGISTRATIONAL TRIAL IN RHEUMATOID ARTHRITIS IN 2026

ARTIVA BIOTHERAPEUTICS INC - INITIAL DATA SHOWS 71% ACR50 RESPONSE IN REFRACTORY RA PATIENTS AT SIX MONTHS

ARTIVA BIOTHERAPEUTICS INC - ALLONK SHOWS FAVORABLE TOLERABILITY PROFILE WITH NO CRS, ICANS, OR DISCONTINUATIONS

ARTIVA BIOTHERAPEUTICS INC - REGISTRATIONAL TRIAL INITIATION EXPECTED IN H2 2026, PRIMARY DATA IN H2 2028

Source text: ID:nGNX2tbZxD

Further company coverage: ARTV.O

 ((((Reuters.Briefs@thomsonreuters.com;));))